Loading stock data…
ALVO
$3.46+0.12 (+3.59%)
Market ClosedLast close May 1
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alvotech in the Healthcare sector is trading at $3.46. The stock is currently near its 52-week low of $3.03, remaining 42.2% below its 200-day moving average. Technical signals show neutral RSI of 40 and bullish MACD crossover, explaining why ALVO maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.46
Potential Downside
54.2%
Whystock Fair Value$1.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
35.00
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.81%
Volume
Today's trading volume
183,113
Recent News
Alvotech (ALVO) Valuation Gap Under Review After Mixed Share Performance And Biosimilar Pipeline Progress
Alvotech overview and recent share performance context Alvotech (NasdaqGM:ALVO) develops and manufactures biosimilar medicines across autoimmune, eye, bone disorder, and cancer indications, and its stock performance has been mixed over different recent periods. The share price was flat over the past day, with a 6.4% decline over the past week. Over the past month the stock shows an 8.7% gain, while the past 3 months reflect a 36.6% decline. Year to date, Alvotech has a 32.4% decline, and the...
Here’s What the Street Thinks About Alvotech (ALVO)
Alvotech (NASDAQ:ALVO) is one of the best stocks under $5 with huge upside potential. Alvotech (NASDAQ:ALVO) has received several rating updates from analysts since the release of its fiscal Q4 and full-year 2025 results. On March 23, Barclays cut the price target on the stock to $4 from $5 and maintained an Underweight rating on […]
Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025
Alvotech (NASDAQ:ALVO) ranks among the oversold European stocks to buy. On March 19, Alvotech (NASDAQ:ALVO) revealed its full-year and Q4 2025 earnings results, delivering revenues of $593 million for the year, representing a 21% year-over-year growth and greatly surpassing analyst projections with Q4 EPS of $0.03 versus a predicted loss of $0.0833. Alvotech (NASDAQ:ALVO) has […]
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Strong earnings weren't enough to please Alvotech's ( NASDAQ:ALVO ) shareholders over the last week. We did some...
Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative?
Alvotech recently reported full-year 2025 results, swinging to net income of US$27.92 million from a prior-year net loss of US$231.86 million, alongside updates on FDA feedback, global biosimilar launches, and new commercialization agreements. The combination of returning to profitability, advancing a 30-product biosimilar pipeline, and reaffirming 2026 guidance highlights a business model becoming more diversified across products, partners, and regions. We’ll now examine how Alvotech’s...